Vaxin, Inc. Receives Birmingham Business Journal’s "Pacesetter" Award

Published: Apr 30, 2010

Birmingham, Alabama – April 27, 2010 – Vaxin Inc., an emerging vaccine company today announced that it has received The Birmingham Business Journal’s (BBJ) Pacesetters Award, as the “Fastest Growing Emerging Company” in the Birmingham area. The award recognizes Vaxin’s outstanding growth rate over the last three years, as well as the company’s continued innovations in vaccine discovery and development.

“It is an honor and privilege to be recognized amongst some of the most dynamic business leaders in the region,” said Bill Enright, President and Chief Executive Officer of Vaxin, Inc. “The past several years have been significant for Vaxin as we have continued to move closer to our goal of developing safe and effective, single-dose, needle-free vaccines for multiple markets. We are well-poised to continue our growth and look forward to advancing our potential products through late-stage clinical testing."

“Pacesetters was created to recognize rapidly growing companies in our area,” said BBJ Publisher Joel Welker. “Specifically, this award acknowledges those private companies that skillfully navigate a competitive national and international marketplace and are growing quickly to be leaders in their field.”

The Pacesetters list was determined by survey information gathered and analyzed by the BBJ from private companies throughout the Birmingham region. The 2010 Pacesetters winners were honored recently at the annual BBJ Pacesetters Luncheon at the Harbert Center in Birmingham, where Mr. Enright delivered the keynote address.

About Vaxin:

Vaxin Inc. is an emerging clinical stage vaccine company developing needle-free, single dose highly safe and effective vaccines. These molecular vaccines are safely administered either in the nose or on the skin, taking the battle against diseases to the immune system’s front lines where the diseases are attacking, rather than injecting the vaccine inside the body where the body’s immune response is actually weaker. This delivery mechanism also allows Vaxin’s vaccines to be mass administered by personnel without sophisticated medical training.

As a vaccine delayed may be a vaccine denied, it is crucial to produce vaccines in a timely manner, especially in the event of a pandemic or bioterrorist attack. The company’s technology platform provides a critical tool for the rapid production of vaccines against influenza, avian influenza and anthrax utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin’s vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics.

Vaxin’s unique technology was developed by Dr. De-chu C. Tang, Vaxin’s scientific founder and Vice President of Research. Unlike current vaccines, which typically use a weakened form of the targeted disease, such as the influenza virus, Vaxin’s molecular vaccines are created by inserting only a piece of the influenza virus (the gene encoding an antigen) into a benign delivery vehicle. This “Trojan Horse” method increases the safety of the vaccine and virtually eliminates the risk of a vaccine reverting to a disease causing agent. Needle-free, non-replicating, single-dose molecular vaccines also have many other advantages. Patients clearly prefer vaccines which are not injected because there is no fear of needles or the pain they can cause.

Vaxin’s technology also has applications for animal health. Automated in ovo (in the egg) vaccination is the method of choice for the mass immunization of poultry because of the ease of administration and lower costs. Unlike most technologies that have been tried, Vaxin’s technology safely introduces a protective vaccine into the egg without harming the embryo.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Back to news